Key result
Postoperative blood glucose > 13.0 mmol/L was an independent predictor of in-hospital mortality (adjusted OR 3.418) in non-diabetic patients with rheumatic heart disease undergoing valve replacement.
Why the study?
Blood glucose is a known risk factor for adverse prognosis in non-diabetic patients across several conditions, but limited studies have explored its relationship with outcomes in non-diabetic patients with rheumatic heart disease.
Does elevated postoperative blood glucose predict in-hospital and one-year mortality in non-diabetic patients with rheumatic heart disease undergoing valve replacement?
Cohort (n=1,395)
No
Does elevated postoperative blood glucose predict in-hospital and one-year mortality in non-diabetic patients with rheumatic heart disease undergoing valve replacement?
In non-diabetic patients with rheumatic heart disease undergoing valve replacement, a postoperative blood glucose level > 13.0 mmol/L is a strong independent predictor of in-hospital and one-year mortality.
May prompt enhanced postoperative glucose surveillance in non-diabetic RHD valve patients; hypothesis-generating for prospective trials.
BACKGROUND: Blood glucose (BG) is a risk factor of adverse prognosis in non-diabetic patients in several conditions. However, a limited number of studies were performed to explore the relationship between postoperative BG and adverse outcomes in non-diabetic patients with rheumatic heart disease (RHD). METHODS: We identified 1395 non-diabetic patients who diagnosed with having RHD, and underwent at least one valve replacement and preoperative coronary angiography. BG was measured at admission to the intensive care unit (ICU) after surgery. The association of postoperative BG level with in-hospital and one-year mortality was accordingly analyzed. RESULTS: Included patients were stratified into four groups according to postoperative BG level's (mmol/L) quartiles: Q1 (< 9.3 mmol/L, n = 348), Q2 (9.3-10.9 mmol/L, n = 354), Q3 (10.9-13.2 mmol/L, n = 341), and Q4 (≥ 13.2 mmol/L, n = 352). The in-hospital death (1.1% vs. 2.3% vs. 1.8% vs. 8.2%, P < 0.001) and MACEs (2.0% vs. 3.1% vs. 2.6% vs. 9.7%, P < 0.001) were significantly higher in the upper quartiles. Postoperative BG > 13.0 mmol/L was the best threshold for predicting in-hospital death (area under the curve (AUC) = 0.707, 95% confidence interval (CI): 0.634-0.780, P < 0.001). Multivariate logistic regression analysis indicated that postoperative BG > 13.0 mmol/L was an independent predictor of in-hospital mortality (adjusted odds ratio (OR) = 3.418, 95% CI: 1.713-6.821, P < 0.001). In addition, Kaplan-Meier curve analysis showed that the risk of one-year death was increased for a postoperative BG > 13.2 (log-rank = 32.762, P < 0.001). CONCLUSION: Postoperative BG, as a routine test, could be served as a risk measure for non-diabetic patients with RHD.
No takes yet. Share an insight, caveat, or question.
Hong et al. (2019) conducted a cohort in Rheumatic heart disease (n=1,395). Postoperative blood glucose > 13.0 mmol/L vs. Postoperative blood glucose ≤ 13.0 mmol/L was evaluated on In-hospital all-cause mortality (OR 3.418, 95% CI 1.713-6.821, p=<0.001). Postoperative blood glucose > 13.0 mmol/L was an independent predictor of in-hospital mortality (adjusted OR 3.418) in non-diabetic patients with rheumatic heart disease undergoing valve replacement.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: